BioPharma Resources

Drugs by condition

Drugs approved for c. difficile infection

Brand-name prescription drugs and biologics whose FDA label lists c. difficile infection as an approved use. Matched on the label phrases: "Clostridioides difficile", "Clostridium difficile".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

7

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

3

New molecular entities and new biologics

In development

4

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for c. difficile infection.

  • Vancomycin Hydrochloride (Vancomycin Hydrochloride) · Zhejiang Novus Pharm Jan 20, 2023
  • Dificid (Fidaxomicin) · Cubist Pharms LLC Priority reviewOrphanJan 24, 2020
  • Firvanq Kit (Vancomycin Hydrochloride) · Azurity Priority reviewJan 26, 2018
  • Zinplava (Bezlotoxumab) · Merck Sharp Dohme NovelPriority reviewOct 21, 2016
  • Dificid (Fidaxomicin) · Cubist Pharms LLC NovelPriority reviewOrphanMay 27, 2011

All approved drugs for c. difficile infection, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 20 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Macrolide Antibacterial (2)

  • Dificid Fidaxomicin · Cubist Pharms LLC · 2011
  • Dificid Fidaxomicin · Cubist Pharms LLC · 2020

Class not listed in FDA's data (5)

Drugs in development for c. difficile infection

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • LMN-201Phase 31 trial

    Lumen Bioscience, Inc. · Clostridioides Difficile Infection

  • VE303Phase 31 trial

    Vedanta Biosciences, Inc. · Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence

  • AZD5148Phase 21 trial

    AstraZeneca · Clostridioides Difficile Infection

  • IbezapolstatACX-362EPhase 21 trial

    Acurx Pharmaceuticals Inc. · Clostridium Difficile Infection Recurrence

More on c. difficile infection: recruiting trials · published research

Related in infectious disease and vaccines: HIV · Hepatitis B · Hepatitis C · COVID-19 · Influenza · RSV · Urinary tract infection · Pneumonia · Skin infections · Fungal infections

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.